Effect of Non-surgical Periodontal Therapy in Hypertensive Patients With Assessment of Endocan and TNF-α Levels in GCF

Launched by AIN SHAMS UNIVERSITY · Oct 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how non-surgical treatment for gum disease (periodontitis) might affect patients who have high blood pressure (hypertension). Researchers want to see if there is a connection between gum health and certain substances in the mouth that can indicate inflammation. Specifically, they are interested in how treatment might change the levels of two markers, Endocan and TNF-α, in the fluid around the gums before and after the treatment.

To participate in this study, you need to be between 30 and 70 years old, have stage II periodontitis, and have controlled hypertension (meaning your blood pressure is within a healthy range). You'll also need to have at least 20 natural teeth and be willing to follow care instructions after treatment. Unfortunately, smokers, pregnant or breastfeeding women, and those with other serious health conditions like diabetes or cancer cannot join. If you qualify, you'll receive non-surgical gum treatment and will be monitored to see how your condition improves. This study could help improve understanding of the link between gum disease and high blood pressure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with stage II periodontitis and controlled hypertension (self-reported history of a diagnosis of HTN by a physician and blood pressure (SBP \< 140 and DBP \< 90).
• • Both genders aged from 30-70.
• • Minimum 20 natural teeth excluding third molars.
• • Good compliance with the plaque control instructions following initial therapy.
• • Availability for follow-up and maintenance program.
• Exclusion Criteria:
• • Smokers.
• • Pregnant and lactating females.
• • Patients with other systemic diseases, such as diabetes mellitus, rheumatoid arthritis and cancer.
• • (According to Cornell Medical Index-Health Questionnaire).
• • Patients taking antibiotic, anti-inflammatory, and immunosuppressive therapy during the preceding 3 months before the start of the trial and during the study.
• • Patients who have undergone any periodontal therapy in the last 6 months.